<DOC>
	<DOCNO>NCT00540410</DOCNO>
	<brief_summary>Primary objective : demonstrate non-inferiority PCR adjust adequate clinical parasitological response D28 artesunate + amiodaquine versus artemether + lumefantrine , base first malaria attack subject . Secondary objective : For first attack : To compare two group treatment term : - D14 efficacy - Parasitological fever clearance - Clinical biological tolerability - Evolution gametocyte carriage - Cardiac tolerability ( QTc ) For repeat attack : To compare two group treatment term : - D14 D28 clinical parasitological effectiveness ( PCR adjust ) - Clinical biological tolerability - Proportion patient without fever D3 - Proportion patient without parasite D3 - Compliance - Impact anaemia During total follow-up cohort : To compare two group treatment term : - Treatment incidence density - Impact repeat treatment clinical biological safety - Impact repeat treatment hearing capacity</brief_summary>
	<brief_title>Cohort Study Senegal Comparing Artesunate + Amiodaquine Treatment Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<criteria>Lists Inclusion Exclusion criterion : adult child weight 5 kg axillary temperature &gt; =37.5Â°C D0 history fever within previous 24hrs confirm Plasmodium falciparum monoinfection , parasitemia &gt; 1000mcl negative urinary pregnancy test woman child bear age new administration treatment presence serious clinical danger sign malaria : prostration , consciousness disorder , recent repeat convulsion , respiratory distress , inability drink , uncontrollable vomiting , macroscopic haemoglobinuria , jaundice , haemorrhagic shock , systolic BP &lt; 70 mmHg adult &lt; 50 mmHg child , spontaneous bleeding , inability sit stand severe concomitant disease allergy one investigational drug . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>